BioNTech SE (BioNTech SE) EV-to-EBIT : 4.58 (As of May. 05, 2024)

View and export this data going back to 2019. Start your Free Trial

What is BioNTech SE EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, BioNTech SE's Enterprise Value is $4,537 Mil. BioNTech SE's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $991 Mil. Therefore, BioNTech SE's EV-to-EBIT for today is 4.58.

The historical rank and industry rank for BioNTech SE's EV-to-EBIT or its related term are showing as below:

BNTX' s EV-to-EBIT Range Over the Past 10 Years
Min: -148.06 Med: 1.69 Max: 33.05
Current: 4.58

During the past 8 years, the highest EV-to-EBIT of BioNTech SE was 33.05. The lowest was -148.06. And the median was 1.69.

BNTX's EV-to-EBIT is ranked better than
56.45% of 434 companies
in the Biotechnology industry
Industry Median: 8.915 vs BNTX: 4.58

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. BioNTech SE's Enterprise Value for the quarter that ended in Dec. 2023 was $7,282 Mil. BioNTech SE's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $991 Mil. BioNTech SE's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 13.61%.

BioNTech SE EV-to-EBIT Historical Data

The historical data trend for BioNTech SE's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioNTech SE EV-to-EBIT Chart

BioNTech SE Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

-36.01

-104.85

3.59

1.68

7.38

BioNTech SE Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial															1.68	2.03	1.71	2.85	7.38

Competitive Comparison of BioNTech SE's EV-to-EBIT

For the Biotechnology subindustry, BioNTech SE's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioNTech SE's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioNTech SE's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where BioNTech SE's EV-to-EBIT falls into.

BioNTech SE EV-to-EBIT Calculation

BioNTech SE's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	4536.632	/	991.064
	=	4.58

BioNTech SE's current Enterprise Value is $4,537 Mil.
BioNTech SE's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $991 Mil.

BioNTech SE (NAS:BNTX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

BioNTech SE's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	991.064	/	7281.64104
	=	13.61 %

BioNTech SE's Enterprise Value for the quarter that ended in Dec. 2023 was $7,282 Mil.
BioNTech SE's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $991 Mil.

BioNTech SE EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of BioNTech SE's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

BioNTech SE (BioNTech SE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioNTech SE (NAS:BNTX) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

BNTX:Mexico 0A3M:UK 22UA:Germany B1NT34:Brazil BNTX:Austria

Address

An der Goldgrube 12, Mainz, RP, DEU, D-55131

Website

https://www.biontech.de

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. COVID-19 vaccine Comirnaty is its first commercialized product.